The Pasteur Museum is housed in the apartment where Louis Pasteur spent his final seven years and offers a rare behind-the-scenes look at the living and working environment of the world-renowned scientist. Visitors can gain a unique insight into his everyday life alongside his wife and can admire his rich and diverse scientific work.
The Institut Pasteur’s scientific strategy focuses on developing original and innovative topics and promoting interdisciplinary and multidisciplinary cooperation and approaches. The Institut Pasteur teams have access to the technological resources needed to speed up and further improve the quality of their outstanding research.
Ever since the introduction of the world’s first "Technical Microbiology" course in 1889, teaching has been a priority for the Institut Pasteur. The Institut Pasteur has an international reputation for quality teaching that attracts students from all over the world who come to further their training or top up their degree programs.
The mission of the Industrial Partnership team is to detect, promote, assist and protect the inventive activities from research (inventions, know-how and biological materials) conducted at the Institut Pasteur (and in some Institutes of its international network), and transfer there to industrial and/or institutional partners, in order to serve the patient needs and for the benefit of the society, as well as to contribute to sustainability of the Institut Pasteur’s resources.
With international courses, PhD and postdoctoral traineeship, each institute of the Institut Pasteur International Network (RIIP) contributes to the transmission of knowledge with the training of young researchers all around the world. In this context, doctoral and postdoctoral programmes, study and traineeship fellowships are available to scientists. Alongside training, dynamism and attractiveness of RIIP will result in the creation of 4-year group for the young researchers.
Scientists from the Institut Pasteur, the French National Center for Scientific Research (CNRS), and the French National Institute for Health and Medical Research (Inserm) have shown that a cellular protein, APOBEC3A, known for its antiviral activity, is also capable of mutagenic activity on human cell DNA. This discovery suggests that this protein plays a role in the cellular DNA degradation occurring in apoptosis, programmed cell death, and cancer genesis. This work has been published on the PNAS website.
Paris, march 7, 2011
Scientists from the Institut Pasteur and the CNRS, making up the Molecular Retrovirology Unit, along with Inserm colleagues, have identified a new function of APOBEC3A, a protein responsible for blocking viral replication in the case of infection. The teams have shown that this protein can induce mutations in its own DNA.
APOBEC3 cellular proteins are known for their antiviral activity. These proteins block the replication of viruses by generating numerous mutations thus "machine-gunning" the viral genome. This is most notably the action taken against AIDS, hepatitis B, and papillomaviruses.
Scientists have shown that under certain cellular conditions APOBEC3A directs its mutagenic activity against its own nuclear and mitochondrial DNA. Given that mitochondrial DNA is directly involved in apoptosis, or programmed cell death, this new identification of APOBEC3A activity suggests that it is part of the phenomenon.
Additionally, in-depth analyses have already shown that the most frequently observed mutations in cancerous cells carry the same signature as those seen with APOBEC3A in nuclear DNA. This indicates the possible involvement of this protein in mechanisms linked to cancer genesis.
This work could open new therapeutic avenues towards the development of molecules capable of blocking this powerful human DNA mutator.
Somatic hypermutation of human mitochondrial and nuclear DNA by APOBEC3 cytidine deaminases, a pathway for DNA catabolism, PNAS en ligne.
Rodolphe Suspène a,1, Marie-Ming Aynaud a,1, Denise Guétard a, Michel Henry a, Grace Eckhoff a, Agnès Marchio b, Pascal Pineau b, Anne Dejean b, Jean-Pierre Vartanian a, and Simon Wain-Hobson a
(a) Institut Pasteur, unité de Rétrovirologie moléculaire, Centre national de recherche scientifique URA 3015, 75724 Paris cedex 15, France
(b) Institut Pasteur, unité de recherche Organisation nucléaire et oncogenèse, Institut national de la santé et de la recherche médicale U993, 75724 Paris cedex 15, France
1 Both authors have contributed equally to this study.